SLC7A7: A Potential Drug Target and Biomarker for Diseases (G9056)

Target Name: SLC7A7

NCBI ID: G9056

SLC7A7

SLC7A7: A Potential Drug Target and Biomarker for Diseases

SLC7A7 (MOP-2), a gene located on chromosome 7, is a protein that plays a crucial role in the development and progression of various diseases, including cancer. The MOP-2 gene has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SLC7A7 is a transmembrane protein that is expressed in most tissues of the body. It is a member of the superfamily of cullin 3 (SLC) proteins, which are known for their ability to interact with various types of molecules, including nucleotides, phospholipids, and proteins. SLC7A7 is characterized by its ability to form a monomeric complex with the protein p120GAP, which is a key regulator of the cullin 3 family of proteins.

The MOP-2 gene has been shown to be involved in a wide range of cellular processes, including cell signaling, DNA replication, and apoptosis. It is highly expressed in many tissues of the body, including the brain, heart, and gastrointestinal tract, and has been implicated in the development and progression of several diseases.

One of the most promising aspects of SLC7A7 is its potential as a drug target. The MOP-2 protein has been shown to play a role in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It is also involved in the development of certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

In addition to its potential as a drug target, SLC7A7 has also been identified as a potential biomarker for several diseases. The MOP-2 protein is expressed in many different types of cells in the body, including neurons and glial cells, which are important for the development and progression of neurodegenerative diseases. Therefore, it may be a useful biomarker for tracking the progression of these diseases.

SLC7A7 has also been shown to play a role in the regulation of cellular processes that are important for cancer development. It is highly expressed in many types of cancer cells, including those of the breast, lung, and ovarian cancers. Therefore, it may be a useful target for cancer therapies that target these cancers.

In conclusion, SLC7A7 is a protein that has the potential to be a drug target and biomarker for a wide range of diseases. Its involvement in the development and progression of neurodegenerative diseases, autoimmune disorders, and cancer makes it an attractive target for further research and development. Further studies are needed to fully understand the role of SLC7A7 in these processes and to develop effective therapies that target this protein.

Protein Name: Solute Carrier Family 7 Member 7

Functions: Heterodimer with SLC3A2, that functions as an antiporter which operates as an efflux routeby exporting cationic amino acids from inside the cells in exchange with neutral amino acids plus sodium ions and may participate in nitric oxide synthesis via the transport of L-arginine (PubMed:9878049, PubMed:9829974, PubMed:17329401, PubMed:10080182, PubMed:10655553, PubMed:15756301, PubMed:15776427, PubMed:14603368). Also mediates arginine transport in non-polarized cells, such as monocytes, and is essential for the correct function of these cells (PubMed:15280038, PubMed:31705628). The transport mechanism is electroneutral and operates with a stoichiometry of 1:1 (By similarity). In vitro, Na(+) and Li(+), but also H(+), are cotransported with the neutral amino acids (By similarity)

The "SLC7A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC7A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets